Expanding Capabilities

Child Formulation

The Pediatric Formulation Gap

Pharma's Almanac

Pathfinder

Conventional Peptide Synthesis vs. Recombinant Peptide Production: Which Manufacturing Strategy Is Better?

Nice Insight

Productivity

The Next Productivity Leap in Mammalian Cell Culture

Pharma's Almanac

Capacity

Is the Bioreactor Arms Race Over?

David Alvaro, Ph.D.

Pharma's Almanac

Biologics

Commercial Thinking Begins in Clinical Phases

Mathias Kahl

IDT Biologika

TPDs

Low Dose, High Impact: Microdosing, Content Uniformity, and Precision Control in TPDs

David O’Connell

PCI Pharma Services

Pathfinder

Digital Twins vs. Traditional Scale-Up Models: Which Approach Is Better for Bioprocess Development?

Nice Insight

Chinese Biopharma

Pharmaceutical Innovation in China Takes Center Stage

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Preparedness

Preparing Manufacturing Networks for the Next Pandemic

Pharma's Almanac

AOCs

Antibody–Oligonucleotide Conjugates Clinical Manufacturing — A New Paradigm Shift of Bio-Conjugates for Therapeutics

Muctarr Sesay, Ph.D.; Natalia Bourguignon, Ph.D.

GBI Biomanufacturing